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ABSTRACT 
 
Reed B. Jacob: Developing a bioscavenger against organophosphate nerve agents 
(Under the direction of Nikolay V. Dokholyan) 
 
Organophosphate poisoning can occur from exposure to agricultural pesticides or 
chemical weapons. This exposure inhibits acetylcholinesterase resulting in increased 
acetylcholine levels within the synaptic cleft causing loss of muscle control, seizures, and death. 
Mitigating the effects of organophosphates in our bodies is critical and yet an unsolved 
challenge. Weaponized organophosphates are a deadly threat to armed forces and civilians (e.g., 
exposure to one droplet of VX exceeds the LD50 of ~15 μg/kg). Here, we present two 
computational strategies to 1) identify a novel protein acting as a stoichiometric bioscavenger to 
covalently bind organophosphates, and 2) improve the stability and activity of organophosphate 
hydrolase as a catalytic bioscavenger through allosteric modulation.  
We use our first computational strategy, integrating structure mining and modeling 
approaches, to identify novel candidates capable of interacting with a serine hydrolase probe 
(either covalently or with equilibrium binding constants ranging from 20 to 120 µM). One 
candidate Smu. 1393c catalyzes the hydrolysis of the organophosphate omethoate (kcat/Km of 
(2.0±1.3)×10-1 M-1s-1) and paraoxon (kcat/Km of (4.6±0.8)×103 M-1s-1), V- and G-agent analogs 
respectively. In addition, Smu. 1393c protects acetylcholinesterase activity from being inhibited 
by two organophosphate simulants. We demonstrate that the utilized approach is an efficient and 
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highly-extendable framework for the development of prophylactic therapeutics against 
organophosphate poisoning. 
Organophosphate hydrolase (OPH) degrades many classes of organophosphates and 
plays an important role in organophosphate remediation. Here, we demonstrate our second 
computational strategy of protein design to enhance OPH’s enzymatic hydrolysis of 
organophosphates and test on paraoxon, a G-agent analog, and omethoate, a V-agent analog. We 
identify five hotspot residues for allosteric regulation and assay these mutants for hydrolysis 
activity against paraoxon. A number of the predicted mutants exhibit enhanced paraoxon activity 
over wild type OPH (kcat =907 s-1), such as T54I/T199I (1260 s-1) while the Km remains 
relatively unchanged. Computational protein dynamics study reveals four distinct distal regions 
that display significant changes in conformation dynamics. The enzymatic enhancement of OPH 
validates a computational design method that is both efficient and readily adapted as a general 
procedure for enzymatic enhancement. 
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CHAPTER 1: CHEMICAL WEAPONS OF MASS DESTRUCTION – A 
JOURNEY THROUGH HISTORY 
 
Organophosphate chemicals have been used as agricultural pesticides since their 
discovery in the early 20th century. It was not until the culmination of World War I (WWI) that 
the governments of the world turned to chemical weapons and their development.1 The first 
weaponized form of organophosphate chemicals was the organophosphate nerve agent (OPNA) 
tabun, first discovered in 1936 by Dr. Gerhard Schrader, an agricultural scientist.1 OPNAs are 
small molecules comprised of both carbon atoms and at least one phosphate usually a chiral 
center, attached to different side groups. It is the identity of these groups that define the level of 
lethality associated with each organophosphate. OPNAs attack and inhibit acetylcholinesterase 
(AChE) preventing acetylcholine clearage from the synaptic cleft indiscriminately of whether the 
host is an insect or a mammal leading to many muscular and neuronal symptoms such as 
bradycardia, bronchoconstriction, and peripheral nerve disease.2–4 Since their discovery many 
new OPNAs have been developed and categorized into the phosphotriester G-agents, and the 
phosphonothioate ester V-agents. When exposed to OPNAs the level of damage can be from 
mild to severe. The length and duration of exposure and the class of OPNAs determine the 
amount of time between exposure and symptom onset with initial symptoms starting mere 
minutes after exposure.5–7 In many cases there is often insufficient time to administer treatment 
before death, such as exposure to soman (GD) leaving a window of treatment of two to six 
minutes.8,9 If treatment is administered in time the approved method of post exposure treatment 
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is a combination of oximes and atropines, which has the potential to reactivate AChE, though 
limited in effectiveness.   
Due to the simplistic nature of these deadly chemical weapons, it is of great concern to 
develop means to protect against accidental exposure, in the case of pesticides, and purposeful 
exposure, in the case of terrorist attacks. This chapter will detail the mechanism of AChE 
inhibition, the nature of OPNAs with a brief history, the effects of AChE inhibition, and 
protection efforts currently under investigation.  
 
Acetylcholinesterase structure and mechanism 
 
Acetylcholinesterase is an enzyme located at synaptic junctions and is responsible for the 
degradation of the neurotransmitter acetylcholine, ending the current signal and preparing the 
junction to receive a new one. AChE falls in the family of enzymes known as cholinesterases. 
The dominant feature of a cholinesterase is an esteric site consisting of a catalytic triad of three 
amino acids, serine, histidine, and glutamic or aspartic acid. In AChE the correct combination of 
these amino acids (Ser203, His447, and Glu334) leads to an activated serine that is capable of 
performing nucleophilic SN2 attack. (Figure 1.1a) The histidine is positioned to attract the 
hydrogen from serine thereby making serine negatively charged. This negative serine then 
attacks the carbonyl carbon of acetylcholine hydrolyzing the carbon-oxygen bond causing 
acylation of the serine. The deacylation of the serine proceeds when a water molecule attacks the 
now acylated serine and restores its functionality. (Figure 1.1b) This process is quick and 
efficient occurring at a rate approximating the diffusion limit (kcat/Km of 1.5×108 M-1s-1) making 
AChE essential to brain-muscle communication.10,11  
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Figure 1.1 AChE functional mechanism. A) The nucleophilic attack of SER203 releasing 
choline. B) A water molecule attacks the acylated serine restoring AChE functionality and 
releasing acetate. 
 
Of key importance are three coordinating sites that help to direct acetylcholine into the 
proper orientation for hydrolysis. These sites consist of the oxyanion hole, an acyl pocket, and an 
anionic site.12 The oxyanion hole is a necessary component for stabilization of the choline group 
in acetylcholine and operates by backbone amide groups (Gly121, Gly122, and Ala204) oriented 
to stabilize the negative charge from the deprotonated oxygen. The acyl pocket is comprised of 
aromatic amino acids, specifically two phenylalanine residues (Phe288 and Phe290) and is 
responsible for stabilizing the acetyl group in preparation for hydrolysis. The anionic site is 
responsible for stabilizing the partial positive from the choline group and contains a tryptophan 
as elucidated by an affinity labeling study (Trp84).13 The complexity of the AChE active site 
allows many different targets for drug therapies, including treatments for Alzheimer’s, 
Parkinson, and other neurodegenerative diseases.14–18 
When the function of AChE is interrupted there is an increase of the neurotransmitter 
acetylcholine within the synaptic cleft, effectively preventing signals from being cleared, making 
the brain unable to communicate causing loss of function that if left unchecked will lead to 
permanent damage even death for the exposed organism. This process is exactly what makes 
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organophosphates so dangerous. Organophosphates (OPs) are small molecules comprising 
carbon atoms and a phosphate chiral center and are detrimental to human health because of their 
ability to inhibit AChE (Figure 1.2). The difference in side groups defines class and lethality of 
OPs. When AChE encounters an organophosphate it attempts to hydrolyze the molecule, 
cleaving the phosphate-oxygen bond in a similar manner to the carbon-oxygen bond in 
acetylcholine. The first half of the reaction proceeds as expected leaving a phosphorylated serine. 
The problem arises that the water molecule does not present a large enough electronegative 
environment to overcome the favorability of the phosphate oxygen covalent bond, thus is unable 
to successfully reactivate the serine.  
 
Figure 1.2 AChE inhibition by OPs. The mechanism by which OPs inhibit AChE, including 
the process of aging. 
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If caught in a timely manner it is possible to reactivate AChE after inhibition. This is 
accomplished through the use of oximes, such as pralidoxime. After the phosphorylation event 
occurs, if an oxime is presented to the inhibited AChE, it is possible to successfully reverse 
inhibition. This restoration of AChE activity occurs when the alcoholic oxygen of the oxime acts 
as a nucleophile to attack the phosphate, releasing the OP from the serine of AChE. (Figure 1.3)  
 
 
Figure 1.3 Reactivation of AChE using oximes. The mechanism by which oximes, specifically 
pralidoxime, can restore AChE’s function prior to irreversible aging. 
 
The ability to successfully reverse inhibition is only possible for a limited window post 
exposure as the combined AChE-OP complex undergoes a dealkylation event in which a water 
molecule acts as a nucleophile and separates the remaining ester group heightening the strength 
of the AChE-OP complex. (Figure 1.2). When AChE is exposed to OPNAs such as sarin and VX 
the time it takes for half of the AChE-OP complex to age is five hours and 48 hours 
respectively.19 Theoretically, this would provide ample time for treatment, but the reality is the 
effects of AChE inhibition are felt at much shorter time intervals. 
 
Structure/History of organophosphate agents. 
 
As previously stated OPNAs are small molecules consisting of a chiral phosphate center 
with a terminal oxygen/sulfur connected to the phosphate by a double bond, two lipophilic 
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groups directly bonded to the phosphorus, and a leaving group (Figure 1.4a). The composition of 
the lipophilic groups and the leaving group differentiates OP pesticides from OPNAs and 
determines the toxicity level of the chemicals. The chirality around the phosphate is a key 
component for toxicity. The left handed minus chirality (Sp) is traditionally more toxic then the 
right handed plus chirality (Rp) as exemplified by the AChE inhibition rate for Sp-VX is 4×108 
M-1min-1 compared to 2×106 M-1min-1 for Rp-VX.20,21 The arrangement of the lipophilic groups 
in the Sp enantiomer is better suited to align to the AChE active site, as the AChE active site 
chirality is inverted from other serine hydrolases, thereby better stabilizing the transition 
state.12,22,23 Though less toxic, the Rp enantiomer is still more than capable to deal a lethal blow, 
thus making OPNAs an effective chemical weapon and a real threat. 
 
Figure 1.4 Structures of OPNAs. A) A generic structure of an organophosphate. B) Structures 
of the G-agent OPNAs. C) Structures of the V-agent OPNAs. 
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Chemical weapons came to the forefront during WWI, though organophosphates were 
not discovered until later. In fact, it was not until 1936 when Dr. Gerhard Schrader, a German 
agricultural scientist working for IG Farben, began experimenting with organophosphate 
molecules as insecticides and discovered that his newest creation, tabun, was extremely toxic to 
humans. Since this first OPNA was discovered by a German scientist, the nomenclature evolved 
to classify this type of OPNA as G-agents. The characteristics of tabun (GA) include a terminal 
P=O, with lipophilic groups being a tertiary amine group and an ester bonded ethane group and 
the leaving cyanide group (Figure 1.4b). In addition, pure tabun is colorless, odorless, and 
volatile with a mouse LD50 of 119 μg/kg for Sp-tabun and 837 μg/kg for Rp-tabun. Shortly after 
tabun toxicity against humans was revealed the German government started a OPNA 
development program headed by Dr. Schrader in which additional, more toxic variants were 
created, such as Sarin (GB), Soman (GD), and Cyclosarin (GF) (Figure 1.4b).  
In response, Great Britain began their own OPNA program resulting in the discovery of 
an even more deadly class of OPNAs, the V-agents starting with VX in the 1950s.24 A 
characteristic difference of this class of OPNAs lies in the ester bonded oxygen to be replaced 
with that of sulfur, defining the class as phosphonothioate esters (Figure 1.4c). In particular, it is 
in the leaving group location where this P-S bond occurs. In the G-agents the leaving group is 
small, often just one atom (fluorine), but in V-agents the addition of the Sulfur ester allows for 
an increased size of the leaving group, thereby increasing potential interactions with the AChE 
active site making V-agents more toxic then G-agents. Specifically, the leaving group of VX 
more directly mimics the choline group from acetylcholine. These differences allows VX to be 
more toxic then any of the previous G-agents with an LD50 of 12.6 μg/kg.20 Soon, additional V-
agents were developed, Russian VX (VR) and Chinese VX (CVX) (Figure 1.4c). Since 
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inception, OPNAs have proven highly toxic and have prompted many attempts to formally ban 
their use in warfare and even in research and development, such as the Conference on 
Disarmament in Geneva in the 1980’s. The United States was among the last nation to support 
the ban on OPNAs and did not take part until the CWC (Convention on the Prohibition of the 
Development, Production, Stockpiling and Use of Chemical Weapons and on their Destruction) 
in 1993 where the United States formally recognized the dangerous potential of OPNAs and 
committed itself to their irradication.25  
 
Effects of OP exposure 
 
Another factor involved in treating OP poisoning cases deals with the level of exposure. 
Of great concern is the treatment and management of symptoms from low-level exposure that 
affects the muscarinic and nicotinic acetylcholine receptors located in both the central and 
peripheral nervous systems. The muscarinic receptor is a G-protein-coupled-receptor that 
activates a cascading pathway. The specific symptoms presenting from overstimulation of 
muscarinic receptors include loss of smooth muscle control leading to salivation, lacrimation, 
urination, defecation, gastrointestinal motility and emesis recalled by the common pneumonic of 
SLUDGEM.6,7,26 Alternatively, the nicotinic acetylcholine receptors are gated ion channels that 
quickly perpetuate a signal and are more often found in the central nervous system.27 As with the 
muscarinic receptors, when the nicotinic receptors get overstimulated the onset of symptoms 
such as anxiety, headache, convulsions, weakness and paralysis result.28 In a study cataloging 
accidental exposure in farmers they found the most common reported symptoms include 
headaches, burning eyes, pain in muscles, rash or itchy skin, and blurred vision.2  
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Additionally, it has been reported that sustained low-level OP exposure may affect the 
reproductive system. These symptoms in males often lead to poor semen, reduced seminal 
volume and motility, and decrease of sperm count per ejaculate.29,30 The reproductive symptoms 
when a female is exposed involve menstrual cycle deviations, spontaneous abortions, stillbirths 
and potential birth defects.29,30 Many studies have been conducted to ascertain the specifics of 
the onset of symptoms.  
When OP exposure is acute reaching the level of lethal AChE inhibition occurs within 
minutes. After an acute exposure to OPNAs, if the treatment is not provided in time, the most 
common cause of death is asphyxiation from respiratory failure.31,32 For example, the OPNA 
sarin reeked havoc when used in two terrorist attacks in Japan, leading to 19 dead with thousands 
more injured.33–35 This fact illustrates the dangerous potential OPNAs have in the hands of 
terrorist and foreign nationals and why they pose a real threat to our armed forces and first 
responders. 
 
Current Protective Strategies 
 
In addition to destroying current stockpiles of OPNAs the United States in partnership 
with other nations is working toward preventative measures. Currently the only Food and Drug 
Administration (FDA) approved pretreatment of organophosphate poisoning is pyridostigmine, 
an AChE reversible inhibitor that lessons the effect of OPNA when administered prior to 
exposure.32,36 Pyridostigmine is only mildly effective and is classified as an AChE reversible 
inhibitor. When treated with pyridostigmine the symptoms from AChE inhibition present 
themselves though not as acutely as an irreversible inhibitor like OPNAs. An alternative method 
 10
for protection against OP exposure involves bioscavenger proteins. A bioscavenger is a small 
protein capable of identifying an OPNA and either hydrolyzing the OPNA (catalytic 
bioscavenger), or sequestering the OPNA through a covalent binding event that mimics AChE 
binding becoming permanently inhibited (stoichiometric bioscavenger).  
 
Catalytic Bioscavengers 
 
 Organophosphate degrading enzymes, or catalytic bioscavengers, potentially provides the 
best solution for protection against OPNA exposure. Two main examples of catalytic 
bioscavengers include human paraoxonase 1 (huPON1) and organophosphate hydrolase (OPH). 
HuPON1 is a glycoprotein expressed in the liver with a molecular weight of 43 kDa and is 
named after it was discovered to hydrolyze the degradation of the organophosphate paraoxon as 
well as other lactone and esters.37 HuPON1 has been studied in relation to many major 
neurodegenerative diseases such as Parkinson’s disease, Alzheimer’s disease, and amyotrophic 
lateral sclerosis (ALS).38,39 A critical element in huPON1’s hydrolysis ability is the metal 
coordination of Ca2+ ion.40 There is a substrate-dependent residue at position 192 which whether 
it is a glutamine (Q192) or an arginine (R192) varies the catalytic efficiency from paraoxon 
(R192) to soman and sarin (Q192). 40–43 The difficulty in using huPON1 as an effective catalytic 
bioscavenger is that it natively hydrolyses the less toxic OP enantiomer (Rp) preferentially to the 
more toxic one (Sp).39,41 Additionally, the application of predictive protein design techniques to 
huPON1 is hampered because of the lack of a human crystal structure though there exists a 
crystal structure of a recombinant hybrid mammalian analog constructed from rabbit, mouse, rat 
and human.41,44 Directed evolution has proven to be the most successful in improving the OPNA 
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hydrolysis activity of huPON1 from it’s initial kcat/Km of 104 to 106 M-1 min-1 to a kcat/Km of 106 
to 108 M-1 min-1 for G agents.41,45,46 While successful in increasing the activity of huPON1 for G-
agents, there has been little advancement in the activity of V-agents making it difficult to 
consider huPON1 as a broad spectrum catalytic bioscavenger. 
 The other major catalytic bioscavenger candidate is organophosphate hydrolase (OPH) 
also known as phosphotriesterase (PTE). OPH is a bimetallic protein dimer capable of 
hydrolyzing a multitude of OPNAs including the V-agents. The near native substrate for OPH is 
paraoxon with an enzymatic efficiency of ~108 M-1 s-1 which approaches the diffusion limit.47 
The efficiency of OPH for OPNAs is greatly diminished with kcat/Km between 104 and 105 M-1 s-1 
for G-agents, nearly half the efficiency of paraoxon, and a kcat/Km less than 103 M-1 s-1 for V-
agents.48,49 By application of both directed evolution and computational design the OPH 
efficiency for OPNAs has been increased to a kcat/Km between 105 and 106 M-1 s-1 for G-agents, 
nearly a two magnitude increase, and a kcat/Km between 104 and 105 M-1 s-1 for V-agents.48,50,51 
This surge in activity for both classes of agents makes OPH the leading catalytic bioscavenger 
candidate.  
 
Stoichiometric Bioscavengers 
 
Another avenue approaching the pretreatment of organophosphate poisoning is a 
stoichiometric bioscavenger. Such a treatment would involve a protein capable of covalently 
binding and sequestering any OPNA. The primary protein under investigation is BChE. BChE 
and AChE share the same fold family, that of an α/β hydrolase fold, and ~50% sequence identity 
with key active site residues conserved.52 In addition the active sites of both AChE and BChE 
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align to a 0.6 Å root mean square deviation (RMSD) showing the potential for BChE to 
effectively covalently bind OPNAs (Figure 1.5).  
 
 
Figure 1.5 AChE and BChE active site overlay. The alignment of the active sites of AChE 
(gray) and BChE (red) with key residues shown in stick representation. 
 
Human serum BChE is an effective prophylactic treatment under experimental 
conditions. Specifically, BChE purified from human serum prevented the toxicity induced by 
soman and VX in monkeys with a ~1.2 ratio of BChE:OPNA.53 BChE in its native form is a 
tetrameric structure with a molecular weight of ~300 kDa raising concern that a large enough 
dose to provide sufficient protection against multiple OPNA LD50 would initiate unwanted 
immunological responses.54 In addition, the cost to get purified BChE in sufficient quantities is 
prohibitive. As it stands a large country like the United States can produce a maximum of 5,000 
individual doses.55 This then turns the focus from purified native BChE to that of a recombinant 
version. Work has shown that recombinant BChE is also effective, the problem lies in the lack of 
stability and effectiveness for extended periods of time. Native BChE experiments show a 
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protection level of greater than 80% for 32 hours, whereas the same level for recombinant BChE 
is maintained for just a few hours.53,55 Due to the large molecular weight and difficulty in mass 
production there is need for a different alternative.  We hypothesize the existence of a low 
molecular weight easily produced protein capable of mimicking covalent binding and detail our 
process for its discovery in chapter 2. In chapter 3 we detail our efforts to allosterically enhance 
the activity of a known catalytic bioscavenger, OPH. Finally, in chapter 4 we make final 
observations and comments on potential future directions. 
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CHAPTER 2: DISCOVERY, CHARACTERIZATION, AND INITIAL 
DESIGN OF LOW MOLECULAR WEIGHT PROTEINS WITH 
BIOSCAVENGER POTENTIAL  
 
Since the discovery of OPs in the 1930’s there has been no defense formulated that 
proves effective. The closest candidate is a stoichiometric bioscavenger, a protein capable of 
sequestering the OP in the blood stream prior to acetylcholinesterase (AChE) inhibition. 
Butyrylcholinesterase (BChE) is the leading stoichiometric bioscavenger candidate and has the 
benefit of being a human plasma derived protein so the likelihood of negative immunological 
response is minimal. BChE is a large tetrameric structure whose size limits its ability to be 
readily administered as a muscular injection, and reach effective full body protection.56 In 
addition attempts to create a recombinant version of BChE to a monomer have destabilized the 
protein from multiple days to hours, severely diminishing the length of protective time 
available.57 Probably the most limiting factor is the difficulty of procuring sufficient doses of 
BChE. Currently, throughout the United States there is only enough capacity to produce roughly 
5,000 doses a year.58 These limitations highlight the necessity for the development of a new 
solution.  
We hypothesize that there exists a low molecular weight protein with a known structure 
that can mimic AChE-OP binding, therefore becoming a novel alternative as a stoichiometric 
bioscavenger. To find such a candidate we employ a pattern matching utility created in our lab, 
Erebus, which takes as input Cartesian coordinates of atoms extracted from the target protein.59 
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In our case, we use the polar atoms in the catalytic triad of AChE, the position where OPs are 
known to bind. We further pipe the results from Erebus through our molecular docking suite, 
MedusaDock, to estimate the binding energy of non-covalent forces, giving us a general idea of 
whether the OP of question, VX, will bind in the pocket.60,61 We choose VX as target OP due to 
its extreme lethality and lack of protective or restorative measures (Figure 2.1). After considering 
the results from both the geometric pattern match, Erebus, and the molecular docking energy, 
MedusaDock, we select the three most likely candidates for experimental characterization, 
namely: phosphoribosyl isomerase from Mycobacterium tuberculosis (PDB ID 2Y85), antigen 
85-A from Mycobacterium tuberculosis (PDB ID 1SFR), and Smu. 1393c from Streptococcus 
mutans (PDB ID 4L9A). All three candidates exhibit some form of interaction with OPs, from 
non-covalent interactions, to full covalent binding (Smu. 1393c). We further show that Smu. 
1393c protects the activity of AChE, making Smu. 1393c the leading candidate for an alternative 
stoichiometric OP bioscavenger. In addition we find that Smu. 1393c has measurable activity 
against omethoate (kcat/Km of (2.0±1.3)×10-1 M-1s-1) and paraoxon (kcat/Km of (4.6±0.8)×103 M-
1s-1), V- and G-agent analogs respectively. This finding reveals the potential for Smu. 1393c to 
become a catalytic OP bioscavenger.  
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Figure 2.1 OP structures used in this study. In this figure we show the structure of all of the 
organophosphates used in this study.  
 
Results & Methods 
 
Computational Workflow overview.  
 
We search the entire protein data bank (PDB) with over 100,000 structures to capitalize 
on the natural diversity found in Nature. This process is based on the assumption that there are 
known proteins existing with promiscuous activity similar to our target protein. The basic 
concept is to take an active site or other definable geometric piece of a protein of interest and 
search the PDB to discover any additional proteins that might serve in the same capacity 
regardless of their previous functional annotations. In our case, we seek a low molecular weight 
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protein with similar binding characteristics to AChE and BChE, which can serve as a 
replacement stoichiometric OP bioscavenger. To implement this search we use two main 
computational resources, namely Erebus, a rigid substructure search algorithm, and 
MedusaDock, a small molecular docking algorithm.59–62 The points of decision for the proposed 
workflow are outlined in Figure 2.2. 
To begin, we realize that of over 100,000 structures in the PDB only a small percentage 
fit the required characteristics, namely a low molecular weight (less than 40 kDa) and a 
monomeric subunit biological assembly. Even before implementation of the workflow we 
significantly reduce the number of structures to be searched to ~ 40,000. With a refined PDB 
structure library we define the characteristics of a query scaffold and prepare it for input to 
Erebus, which extracts a geometric distance relationship and rapidly searches the refined library 
to find a match. We access the returned matches visually for duplicates and surface accessibility. 
The reduced candidate pool is then piped into a virtual docking screen using MedusaDock to 
access each candidate’s ability to bind with the selected small molecule. At each point in the 
workflow there is a place to access the current performance with options to return to scaffold 
selection, or filter criteria for the refined database, or even to alter the parameters for the rigid 
substructure search. This workflow is versatile and can easily be adapted to find promiscuous 
activity among proteins with a known structure. We design experiments in which we corroborate 
the three top predicted candidates, thus validating the computational workflow. Key features we 
test for are binding interactions, both non-covalent and covalent, location of binding, and ability 
for the candidates to protect AChE in an in vitro experiment.  
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Figure 2.2 Computational design workflow. In this figure we show the complete 
computational workflow, including all of the steps and decision points that occur in our 
computational design. The asterisks indicate where the two algorithms, Erebus and MedusaDock, 
are used. 
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Identify candidate scaffolds.  
 
Before we perform an effective search we first curate the PDB structures creating a 
subset library of structures focusing on the characteristics of interest. Those characteristics 
include a low molecular weight (less than 40 kDa) and a monomeric biological unit, which we 
screen by requiring that a length less than 350 residues and less than four subunits. We use a 
rigid substructure search algorithm, Erebus, to identify proteins from the PDB that contain 
characteristics essential for OP binding (Figure 2.3a). 
 
 
Figure 2.3 Two-stage search workflow with identified search parameters. A) In this 
illustration we depict the computational protocol as a funnel where the various levels represent 
the initial population of PDB structures (top of funnel), the substructure search algorithm, 
Erebus, the docking algorithm, MedusaDock, and the final predicted candidates (below funnel). 
Alongside the illustration are two columns where we list the filter conditions at each step (first 
column) and the number of resulting structures for that step (second column). The search 
database comprises a snapshot of the PDB database from December 2014. B) We show the 
geometric feature submitted to Erebus, which is comprised of four selected atoms from AChE 
(PDB ID 1F8U) and the connections between them to represent the geometric feature that Erebus 
searches for.  
 
We derive these characteristics from the required amino acids in the binding sites of 
BChE and AChE, the core structure of these proteins is that of an α/β hydrolase fold containing 
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the canonical key residues of the catalytic triad (serine, histidine, and glutamic acid).63 Both 
BChE and AChE proteins have the ability to covalently bind and sequester OPs. The key atoms 
we use to construct our query scaffold are the hydroxyl oxygen from Ser203, the carboxylic 
oxygen from Glu334, the tele nitrogen from His447, all from the catalytic triad as oriented in the 
crystal structure of AChE (PDB ID 1F8U). We also include the indolic nitrogen from Trp86 to 
describe the binding pocket diameter (Figure 2.3b). The structure query is atomic coordinates in 
a PDB file format:  
ATOM   1543  OG  SER A 203     116.605 106.967-138.509  1.00 53.76           O 
ATOM   3355  ND1 HIS A 447     116.432 102.538-135.187  1.00 56.88           N 
ATOM   2485  OE1 GLU A 334     114.554 100.680-134.867  1.00 62.46          O 
ATOM    634  NE1 TRP A  86     125.948 105.322-133.913  1.00 37.58             N 
Erebus takes our query scaffold and extracts the geometric features, such as inter-atomic 
pairwise distances, and searches the refined PDB structure library for any matches. A match is 
defined when a structure aligns with the query scaffold with a root mean square deviation 
(RMSD) below the desired cutoff set at four angstroms. The computational cost of Erebus is 
minimal with the time to search our ~40,000 refined structural library at ~1.5 hours. 
As a positive control, we seed the refined PDB structural library with four AChE crystal 
structures (PDB IDs: 1B41, 1F8U, 3LII, 2X8B) and four BChE crystal structures (PDB IDs: 
1P0I, 1P0M, 2XQF, 2WID). Four of these structures were returned as matches while the 
remaining crystal structures, 2X8B, 1P0I, 2XQF, and 2WID, revealed that they contained 
covalently modified active site serines such that Erebus did not recognize them as matches 
within the set search parameters. A potential solution is a decrease in the sensitivity parameters, 
allowing a greater variability to be considered a positive match. Unfortunately, this decrease 
increases the number of returned results from hundreds to thousands. We hold this solution in 
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reserve to be used when there is no identified result from the more stringent search parameters. 
The returned candidate match list, containing ~230 matches is further reduced by visual 
inspection to remove duplicate proteins, and proteins where the match location is not solvent 
accessible leaving 21 viable candidates for molecular docking screening (Table 2.1). 
 
Table 2.1 Characteristics of potential bioscavenger candidates. For each candidate we list the 
PDB ID, the scaffold RMSD to the control human BChE, the average ligand RMSD to the 
control, the top predicted energy returned by MedusaDock, the residue length, and the molecular 
weight. 
Candidate 
Scaffold 
RMSD (Å) 
Average Ligand 
RMSD (Å) 
Top Docking 
Energy (kcal/mol) 
Residue 
Length 
Molecular Weight 
(kDa) 
1SFR 3.7 6.52 -32.5 304 31.6 
2Y85 2.04 5.22 -29.3 244 26.3 
4L9A 2.37 5.65 -29.0 292 33.5 
3BCN 4.03 8.93 -28.0 209 23.3 
2OZ2 4.1 9.67 -27.5 215 23.7 
2GHU 4.12 8.11 -26.7 241 27.2 
1OCQ 2.03 14.42 -26.6 303 34.6 
1H2J 2.77 8.71 -26.0 303 34.8 
2V38 2.03 15.62 -25.9 305 34.9 
1A3H 2.77 8.91 -25.9 300 33.7 
3GI1 4.69 6.61 -25.5 286 32.0 
3RJX 2.35 7.29 -25.5 320 37.6 
1F29 4.07 9.38 -25.5 215 23.3 
1QHZ 4.05 6.37 -25.2 305 34.4 
1H5V 2.76 9.4 -24.7 304 35.6 
1E5J 2.76 9.06 -24.5 305 35.1 
1MEG 6.07 9.97 -23.1 216 23.7 
2WHJ 2.04 8.61 -22.9 308 34.7 
2OUL 4.15 8.44 -21.6 241 26.9 
3BPF 4.03 8.9 -21.2 241 27.6 
2BDZ 3.98 9.48 -20.9 214 24.2 
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Identification of top-ranked candidates.  
 
Prior to covalent binding interactions it is necessary for non-covalent forces (i.e. charge-
charge interactions and Van der Waals interactions) to assist in proper orientation of the ligand 
for a serine nucleophilic attack. It is these non-covalent forces that we simulate with our docking 
suite MedusaDock. MedusaDock is a unique algorithm that considers the flexibilities of both 
receptor side chains and ligands. The receptor side chains near the binding site can sample all 
possible rotamers. The docking process consists of two steps, 1) a course docking with rigid-
body minimization and 2) a fine-docking step where both side chain and ligand rotamers are 
considered in the final energy. This method of docking allows MedusaDock to successfully 
predict ~80% of blind pose prediction within 2.5 Å in the CSAR 2011 docking benchmark.60,61  
We first test whether MedusaDock is a viable option for our system by redocking a VX 
molecule to the active site of BChE and compare it to the x-ray crystal structure of BChE 
covalently inhibited by VX (PDB ID: 2XQF). We find that the redocking of VX closely aligns 
within the electron density map, thus confirming the successful application of MedusaDock to 
our system (Figure 2.4).  
The input for MedusaDock consists of 1) a target protein in PDB format64, 2) a small 
molecule in a Mol2 file format65, and 3) the location of the search sphere marked by a small 
molecule or atom in a Mol2 file format. We select the top candidates for further characterization, 
both computational and experimental, by ranking the 21 candidates from the Erebus search by 
best-predicted binding energy (Table 2.1). This initial ranking consists of 100 independent 
docking simulations for each candidate with the small molecule VX. This method of ranking 
reveals a natural division between the candidates: 1) an Erebus RMSD less than 4 Å; 2) an  
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Figure 2.4 VX redocking to BChE. We show the validation of MedusaDock where the docked 
VX molecule lies within the electron density map of the phosphorylated serine of BChE (PDB 
ID 2XQF).  
 
average ligand RMSD less than 8 Å; 3) a MedusaDock predicted binding energy less than -28 
kcal/mol. There are three candidates that top this list, namely phosphoribosyl isomerase from 
Mycobacterium tuberculosis (PDB ID 2Y85), antigen 85-A from Mycobacterium tuberculosis 
(PDB ID 1SFR), and Smu. 1393c from Streptococcus mutans (PDB ID 4L9A).  
Having selected the top three candidates we perform an in-depth docking study designed 
to create a predicted binding energy distribution. This process involves running over 1,000 
independent docking simulations for each candidate as well as AChE and BChE controls. Each 
docking simulation takes between 4-6 minutes to complete. Thus, we distribute the 1,000 
docking simulations over the killdevil computer cluster at UNC. When using molecular docking, 
it is important to determine the number of docking runs necessary to reach proper convergence to 
the lowest energy pose. This number is system specific and after a convergence study we 
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determine 1,000 docking simulations are required to compute the predicted binding energy 
distributions. The final distribution of predicted binding energies is a frequency histogram where 
the number of docked poses that fall within a set bin size is plotted. We use this distribution to 
compare the binding modes of VX from the candidate proteins to those obtained in the same 
manner from AChE and BChE (Figure 2.5).  
 
Figure 2.5 Predicted Binding Energy distributions, structural overlays, and active site 
comparisons.  A) (left) We show the predicted binding energy distributions of VX agent docked 
in the binding site of positive controls BChE (PDB ID 2XQF) and AChE (PDB ID 1F8U) (red 
and black curves respectively). (middle) We show that the control proteins show a similar size 
(~84 kDa) by the structural overlay of AChE (gray) and BChE (red). (right-top) We show the 
similarity of both AChE (gray) and BChE (red) active sites in the absence of VX. (right-bottom) 
We show that the lowest energy pose of VX docked with AChE (black) and BChE (gray) place 
the phosphate in the correct orientation to irreversibly bind the active serine. B) (left) We show 
that antigen 85-A (PDB ID 1SFR) (orange curve) is predicted to have binding interactions 
similar to control AChE and BChE (black and red curves respectively), through the overlap of 
predicted binding energy distributions of the organophosphate VX. (middle) We show antigen 
85-A’s lower molecular weight by structurally aligning antigen 85-A (orange) with a molecular 
weight of ~35 kDa to BChE (red) with a molecular weight of ~84 kDa. (right-top) We show that 
the predicted residues of antigen 85-A (orange) align with the active site of BChE (red) in the 
absence of VX. (right-bottom) We show that the lowest energy pose of VX docked with antigen 
85-A (orange) and BChE (gray) place the phosphate in the correct orientation to irreversibly bind 
the active serine. C) (left) We show that phosphoribosyl isomerase (PDB ID 2Y85) (green 
curve) is predicted to have binding interactions similar to control AChE and BChE (black and 
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red curves respectively), through the overlap of predicted binding energy distributions of the 
organophosphate VX. (middle) We show phosphoribosyl isomerase’s lower molecular weight 
by structurally aligning phosphoribosyl isomerase (green) with a molecular weight of ~25 kDa to 
BChE (red) with a molecular weight of ~84 kDa. (right-top) We show that the predicted 
residues of phosphoribosyl isomerase (green) align with the active site of BChE (red) in the 
absence of VX. (right-bottom) We show that the lowest energy pose of VX docked with 
phosphoribosyl isomerase (green) and BChE (gray) place the phosphate in the correct orientation 
to irreversibly bind the active serine. D) (left) We show that Smu. 1393c (PDB ID 4L9A) (blue 
curve) is predicted to have binding interactions similar to control AChE (PDB ID 1F8U) and 
BChE (PDB ID 2XQF) (black and red curves respectively), through the overlap of predicted 
binding energy distributions of the organophosphate VX. (middle) We show Smu. 1393c’s lower 
molecular weight by structurally aligning Smu. 1393c (blue) with a molecular weight of ~33 kDa 
to a monomer of BChE (red) with a molecular weight of ~84 kDa. (right-top) We show that the 
predicted residues of Smu. 1393c (blue) align with the active site of BChE (red) in the absence of 
VX. (right-bottom) We show that the lowest energy pose of VX docked with Smu. 1393c (blue) 
and BChE (gray) place the phosphate in the correct orientation to irreversibly bind the active 
serine.  
 
When comparing the distributions, the greater the overlap suggests the greater likelihood 
of mimicking OP non-covalent binding patterned after AChE and BChE. In addition we examine 
the distance between the VX chiral phosphate and predicted serine and find that within the 
candidates examined in this manner the distance is less than 4 Å. This distance places the VX 
molecule in sufficient proximity to the predicted active serine to provide the correct conditions 
for covalent binding. Additionally when considering the best scoring pose we find that each 
candidate is within a 6 kcal/mol difference to the value of -35.3 kcal/mol as calculated for AChE. 
With the overlapping distributions and the small range in energy differences, our three 
candidates show predicted characteristics similar to AChE. 
 
Protein expression and purification.  
 
Each candidate gene contains an added poly-His tag and TEV protease cut site at the N-
termini and cloned into the pET14B vector for expression in the E. coli strain BL21 (DE3) 
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pLysS. The cells are grown in both standard LB for Smu. 1393c and phosphoribosyl isomerase, 
and super broth for antigen 85-A. In all cases we induce expression with 1 mM of Isopropyl β-D-
1-thiogalactopyranoside (IPTG) at 25°C overnight for phosphoribosyl isomerase and Smu. 
1393c, and 72 hours at 18°C for antigen 85-A. The cells are then pelleted and stored at -80°C 
until use. 
The cells are defrosted and resuspended in a buffer containing 50 mM phosphate pH 7.4, 
500 mM NaCl, 40 mM imidazole, 5 mM βME, and 0.1 μM pepstatin A. We lyse the cells using 
sonication and centrifuge at 15,000 g for two hours. The supernatant is collected and 
filtered through a 0.22 μm syringe filter prior to loading onto a 5 mL HisTrap FF column. 
The purified protein is eluted with a gradient to a buffer containing 50 mM phosphate pH 
7.4, 150 mM NaCl, 1 M imidazole. We then cleave the poly-His tag using TEV protease by 
placing the protein containing fractions in dialysis with TEV in a 1:30 dilution in a buffer 
containing 50 mM phosphate pH 7.4, 500 mM NaCl. After 24 hours the solution is then 
again loaded onto the HisTrap column and the purified protein is collected from the flow 
through. 
 
OP covalent binding to top candidates.  
 
We investigate the potential of our candidates to bind OPs in a similar mechanism as 
AChE. To do this we utilize serine hydrolase probes, specifically ActiveX Tamra 
fluorophosphonate serine hydrolase probe (TFP-probe) and ActiveX Desthiobiotin 
fluorophosphonate serine hydrolase probe (DFP-probe) (Figure 2.1). Each probe is designed to 
be visible in either a fluorescent gel (TFP-probe) or a western blot (DFP-probe). We adjust the 
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protocol and incubate the various hydrolase probes with the candidates at a ration of 1:30 
concentrations. So for 5 μM protein we add 167 nM of the probe. The total reaction size is 20 
μL. Each protein sample and probe is incubated at room temperature for 15-30 minutes. The 
reaction is quenched by adding 5 μL of SDS-PAGE loading dye (200 mM Tris pH 6.8, 10 mM 
βME 10% SNS, 30% glycerol and bromophenol blue) and boiled for 5 minutes. The quenched 
reaction is run on a standard protein gel. This gel is processed following traditional western blot 
techniques, for the DFP-probe, or is simply imaged with a fluorescent gel scanner, for TFP-
probes (Figure 2.6). Each gel contains a negative control with just the protein. A positive band 
from the gels indicates that the candidate successfully formed a covalent bond with the probe in a 
similar manner as OPs inhibit AChE, as anything other than a covalent bond would be washed 
away after denaturation of the protein.  
 
 
Figure 2.6 Experimental results of OP binding. We show that candidate Smu. 1393c (PDB ID 
4L9A) is covalently labeled by two serine hydrolase probes, whereas Smu. 1393c S99A, antigen 
85-A (PDB ID 1SFR), and phosphoribosyl isomerase (PDB ID 2Y85) are not covalently labeled. 
For each serine hydrolase probe we include a parallel coomassie stained SDS-PAGE gel showing 
the presence of protein candidates. 
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It is clear from Figure 2.6 that both the TFP-probe and the DFP-probe show only one 
significant band, that for Smu. 1393c, indicating the covalent bonding potential with 
organophosphates. We realize the potential for non-covalent binding for antigen 85-A and 
phosphoribosyl isomerase. 
We use fluorescence polarization to 1) quantify OP binding, and 2) identify any non-
covalent binding forces acting between the probe and our candidates. These studies use the TFP-
probe as substrate. We dilute the TFP-probe to a 200 nM concentration and titrate the protein, 
measuring the change in polarization until saturation is reached. We fit the data to a one site-
specific binding model  (Figure 2.7 and Equation 2.1). 
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Figure 2.7 Fluorescent polarization representations. We show that candidates antigen 85-A 
(orange), and phosphoribosyl isomerase (green) interact with the serine hydrolase probe in a non-
covalent manner as predicted and confirm the diminished binding of Smu. 1393c S99A (inverted 
blue triangle). Both the original fluorescence polarization and fraction bound plots are 
represented. 
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In quantitating the binding interactions we find that both candidates’ bind the TFP-probe 
with micromolar affinity, antigen 85-A with a Kd of 20.9 ± 1.6 μM and phosphoribosyl 
isomerase with a Kd of 120 ± 10 μM. The presence of any binding affinity, however low, 
suggests that both antigen 85-A and phosphoribosyl isomerase both interact with the TFP-probe 
in a non-covalent manner. All three candidates show binding interactions, confirming the 
prediction of non-covalent forces by our computational workflow.  
 
OP covalent binding to Smu. 1393c active site.  
 
To validate the predictive potential of our workflow we verify the location of the 
predicted site by mutating the predicted active serine (Ser99) to alanine and running the same 
experiments as previously outlined, specifically the active site labeling with both TFP-probe and 
DFP-probe as well as fluorescent polarization experiments with the TFP-probe (Figures 2.6 and 
2.7). The Kd of this Ser99 mutant from fluorescent polarization is greater than 300 μM. The once 
visible band from the successfully labeled wild-type Smu. 1393c disappears when Ser99 is 
mutated to alanine. The lack of a covalent bond in the Ser99 mutant (Figure 2.6) suggests that we 
did in fact predict the correct location of the active site using our computational method.   
 
Smu. 1393c catalytic activity and protection of AChE.  
 
In Wang et el, Smu. 1393c was first crystallized and the activity characterized 
successfully showing by alanine mutation that Ser99, His249, and Glu123 are necessary for the 
observed activity against p-nitrophenyl acetate (PNP-ac)66. These three residues coincide with 
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those identified from our protocol. We duplicate the experimental results and determine the 
activity level of Smu. 1393c against PNP-ac by observing the absorbance of the leaving p-
nitrophenyl group, which absorbs at 405 nm. We perform this assay over a PNP-ac concentration 
range of 0-12 mM. The initial velocities at each concentration are plotted and fit to the 
Michaelis-Menton kinetic equation (Equation 2.3). We find the hydrolysis rate of PNP-ac to be 
kcat/Km of 6.3±1.3 M-1s-1 (Figure 2.8, Table 2.2).  
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Figure 2.8 Non-competitive Smu. 1393c inhibition. A) We show the activity of Smu. 1393c 
against p-nitrophenyl acetate uninhibited (black triangles) and inhibited with demeton-S-methyl 
(DSM) (red circles). B) In this figure we show a Lineweaver-Burk plot of Smu. 1393c activity 
against PNP-ac with and without inhibitor DSM, illustrating the likelihood of non-competitive 
inhibition.  
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Table 2.2 Kinetic parameters for Smu. 1393c. We show the kinetic parameters of Smu. 1393c 
with substrate PNP-ac, and PNP-ac and inhibitor DSM. 
  kcat (s-1)(10-3) Km (mM) kcat/Km (M-1s-1) 
PNP-ac 42±4 6.7±1.3 6.3±1.3 
PNP-ac + DSM 22±3 6.0±1.9 3.6±1.3 
 
However, when we expose Smu. 1393c to the V-agent analog demeton-S-methyl (DSM) 
we find that the activity level is reduced indicating an inhibitory effect. In fact, we perform the 
same kinetic assay with Smu. 1393c and a 10 μM concentration of DSM and calculate the 
inhibition constant using equation 2.4 to be a Ki of 10.64±1.9 µM.  
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Further by examining a double reciprocal plot we find that DSM inhibits Smu. 1393c in a 
non-competitive manner (Figure 2.9b), suggesting a potential second site that when bound has 
direct ramifications on activity. 
This non-competitive inhibition of Smu. 1393c by DSM indicates a protein/ligand 
interaction. The presence of this interaction suggests the potential for bioscavenger behavior. We 
explore the ability of Smu. 1393c to protect AChE from inhibition through a quantitative set of 
activity assays, modified from Cherny et al, designed to gauge the amount of AChE activity 
maintained after exposure to two OP simulates.50 We use two OPs, DSM as a V-agent analog 
and diisopropylfluorophosphate (DFP) as a G-agent analog. We purchase lyophilized 
Electrophorus electricus AChE, DSM, and DFP from Sigma Aldrich. The general procedure is 
as follows: 1) we incubate equal amounts of Smu. 1393c and OP simulant (final concentration 
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500 nM) at 20 oC for 30 minutes; 2) we add AChE to each sample and incubate at 20 oC for 60 
minutes; 3) we add 500 μM of the Ellman reagent 5,5-dithio-bis-(2-nitrobenzoic acid) (DTNB) to 
the samples as a detectable marker; 4) we vary the amount of acetylthiolcholine (0-20 mM) 
and bring each sample to a volume of 50 μL using buffer (200 mM NaCl, 20 mM TRIS at pH 
7.4).  
We perform each assay in triplicate, plot the kinetic parameters, and fit them to the 
Michaelis-Menton kinetic equation (equation 2.3). All measurements are expressed as relative 
activity to uninhibited AChE. We observe that Smu. 1393c protects AChE from full inhibition, 
preserving 84.4±4.1% of activity for DSM and 76±10% for DFP. Additionally, we find no 
significant change between the Km of active AChE (3.05±0.79 mM) and inhibited AChE 
(4.43±0.63 mM for DSM and 3.2±1.3 mM for DFP) (Figure 2.9, Table 2.3). These results 
indicate that Smu. 1393c may act as an OP bioscavenger to protect AChE from inhibition. 
 
Figure 2.9 Smu. 1393c protects AChE function. We show that Smu. 1393c protects AChE 
activity with (i) AChE uninhibited positive control (black), (ii) protected AChE activity from 
demeton-S-methyl (blue filled) and diisopropylfluorophospate (red filled), and (iii) AChE 
inhibited negative controls, demeton-S-methyl (blue outline) and diisopropylfluorophospate (red 
outline). All experiments were run in triplicate.  
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Table 2.3 AChE protection by Smu. 1393c. Kinectic parameters showing positive control 
(uninhibited AChE) and AChE that is protected by Smu. 1393c from both demeton-S-methyl 
(DSM) and diisopropylfluorophosphate (DFP). 
  Km (mM) kcat (s-1) kcat/Km (M-1 s-1) 
AChE 3.05 597.6 2.0 × 105 
AChE/Smu. 1393c/DSM 4.43 504 1.1 × 105 
AChE/Smu. 1393c/DFP 3.24 456 1.4 × 105 
 
 
Smu. 1393c activity against OPs.  
 
We investigate the catalytic potential of Smu. 1393c against OPs. Our first selection of 
OP for V-agent analog is DSM and for a G-agent analog is DFP. Despite finding catalytic 
activity against DSM, we fall short of kinetic saturation due to limited supply. The G-agent 
analog selected, DFP, requires an experimental setup unsupported in our laboratory. For these 
reasons we change from DFP and DSM to paraoxon and omethoate as G- and V-agent analogs 
respectively (Figure 2.1). To monitor the rate of hydrolysis we detect the p-nitrophenyl group at 
an absorbance of 405 nm for G-agent analog paraoxon. For our V-agent analog omethoate we 
use an Ellman assay.67 For each assay we use a range of 0-17 mM omethoate and 0-100 μM 
paraoxon. The final assay volume is brought to 1000 μL with 50 mM bis-tris-propane pH 7.4. 
We initiate the catalytic reaction by adding Smu. 1393c for a final concentration of 72 nM for 
paraoxon, and 5 μM for omethoate. After a series of kinetic assays we find that Smu. 1393c 
catalyzes the hydrolysis of omethoate with a kcat/Km of (2.0±1.3)×10-1 M-1s-1 (Figure 2.10, Table 
2.4). When we test paraoxon hydrolysis the activity level is below the sensitivity of our 
instruments. Intriguingly, when we express Smu. 1393c with zinc and then test activity we see 
hydrolysis of paraoxon with a kcat/Km of (4.6±0.8)×103 M-1s-1 and a loss of detectable omethoate 
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activity. These findings suggest two different catalytic mechanisms. When we perform the same 
experiments with Smu. 1393c S99A mutant we find no activity for either omethoate or paraoxon, 
suggesting that Ser99 is crucial in both mechanisms. 
 
 
Figure 2.10 Smu. 1393c catalytic activity. We show that Smu. 1393c catalyzes the hydrolysis 
of organophosphates omethoate (A) and paraoxon (B) with the initial velocity plot fitted to 
Michaelis-Menten equation.  
 
 
Table 2.4 Kinetic parameters for Smu. 1393c against OPs. We show the kinetic parameters of 
Smu. 1393c with paraoxon and omethoate.  
  kcat (s-1)(10-3) Km (mM) kcat/Km (M-1s-1) 
Paraoxon* 25±0.9 (5.5±1)×10-3 (4.6±0.8)×103 
Omethoate 0.52±0.09 2.6±1.6 0.2±0.13 
* Smu. 1393c expressed with zinc 
 
Discussion 
 
The danger of OP poisoning is real with ~3,000,000 individuals exposed yearly recording 
up to 200,000 fatalities.68,69 To truly make an impact any therapeutics would need to be cheap 
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and effective, especially in developing countries where cheap OP pesticides provide profit in 
their agricultural industries.26 While agricultural OP poisoning is a problem, the grave concern 
lies in the potential exposure from OP chemical nerve agents. These agents are cheap, deadly and 
can easily be used in warfare or a terrorist attack.  We have no current defense other than 
protective equipment and decontamination procedures currently employed by the military.70 
Unfortunately, these measure are most effective if there is advanced knowledge of a potential 
exposure situation. A better alternative is an OP bioscavenger, whether stoichiometric or 
catalytic, that will protect AChE from inhibition by OP chemicals.  
We present three candidates as producible bioscavenger candidates that also have a low 
molecular weight, antigen 85-A and phosphoribosyl isomerase from Mycobacterium tuberculosis 
and Smu. 1393c from Streptococcus mutans. Two of the structures, antigen 85-A and Smu. 
1393c, share a common structure with AChE and BChE, that of an α/β hydrolase. What is 
interesting is that neither candidates has more than five percent identity with AChE and BChE.66 
Whereas phosphoribosyl isomerase has a core structure of a (β/α)8-barrel scaffold, making it 
unique among the candidates.71 We predict non-covalent interactions with OPs for each of these 
candidates and experimentally validate their prediction using serine hydrolase probes. We find 
that the candidates do indeed interact with OPs, such as covalent bond formed by Smu. 1393c 
and the equilibrium binding constants of 20 and 120 μM for antigen 85-A and phosphoribosyl 
isomerase respectively.  
One candidate, Smu. 1393c shows potential for AChE protection as well as activity 
against omethoate (kcat/Km of (2.0±1.3)×10-1 M-1s-1) in the absence of zinc but is active against 
paraoxon (kcat/Km of (4.6±0.8)×103 M-1s-1) when zinc is present, indicating that there may be a 
metal-coordination site present. Further it is possible that the Ser99 is a key element to both 
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modes of catalysis as when the tests are performed with the S99A mutation, no activity is found 
in either condition. Though Smu. 1393c shows promise as an OP bioscavenger, much work 
remains to be done. One key study is the investigation of immunological effects that introducing 
Smu. 1393c into the immune system might cause.  
We demonstrate the effectiveness of our computational workflow by identifying our three 
bioscavenger candidates. This workflow combines two successful algorithms; 1) Erebus59, a 
structural database search algorithm to identify molecules with substructures matching the query 
template; and 2) MedusaDock62, a small molecule docking algorithm to predict the probability of 
interaction. With further automation and development we believe this workflow can easily be 
extended into applications benefitting the pharmaceutical industry and the biotech community. 
Specifically, by aiding in molecular therapeutics, drug repurposing, protein sensor design, 
epitope vaccine design, and drug adverse side-effect studies.  
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CHAPTER 3: COMPUTATIONAL REDESIGN OF ORGANOPHOSPHATE 
HYDROLASE TO ENHANCE ORGANOPHOSPHATE NERVE AGENT 
HYROLYSIS 
 
The existing vulnerability to OPNAs due to limited protective measures is of great 
concern and has spurred investigations into the enzymatic hydrolysis of organophosphates for 
remedial and therapeutic use. The currently used enzyme for remediation is organophosphate 
hydrolase (OPH)72, which is a bi-metallo-coordinated enzyme existing naturally as a homodimer, 
where each subunit contains two zinc ions coordinated to form the binding site (Figure 3.1).  
 
 
Figure 3.1 Structural representation of OPH. Native homodimer structure of organophosphate 
hydrolase. Zinc ions are shown as spheres with paraoxon ligand in stick figure (green). 
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An ideal enzyme engineered for remediation would be capable of degrading multiple 
organophosphate nerve agents. OPH has effect against most nerve agents with published 
hydrolysis rates of a kcat of 0.30 s-1 for V-agent VX and 56 s-1 for G-agent sarin.73,74 The known 
simulant closest to native activity is paraoxon with a published kcat of 2400 s-1.75 
Recent successes in protein design detail the development of small molecule binding 
proteins76,77, an artificial bis[4Fe-4S] binding protein78, and a binding site redesign to favor a 
new substrate79. Additionally, enzyme design has progressed to engineer novel catalytic sites, 
such as for the retroaldolase reaction80, or serine hydrolases81. All of these examples rely on a 
combined protocol merging the power of computational simulation with experimental 
techniques, such as directed evolution.82,83 Here, we present a successful application of purely 
computational predicted design to enhance paraoxon hydrolysis by OPH. 
Our approach is novel in that the enhancement of catalytic activity occurs through the 
modulation of allosteric networks.  Allosterically regulated proteins, such as G protein-coupled 
receptors and kinases, such as receptor tyrosine kinases, have been highly targeted for 
therapeutics.84–93 Identification of key allosteric residues enhance the probability of identifying 
allosteric binding sites for directed drug development.94–96 Currently, only one other reported 
technique probes allosteric mutations, and is computationally intensive requiring both molecular 
mechanics and molecular dynamics combined with docking efforts.97 Our enzyme design 
workflow is computationally efficient and can readily scan potential mutations for a residue 
position in minutes.  
Protein engineering protocols to improve OPH traditionally focus on modifying the 
substrate specificity for unique nerve agents such as VX. Di Sioudi et al. utilized rational design 
to identify OPH mutations that increase kcat of VX by fourfold.98 Bigley et al. included directed 
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evolution leading to a kcat increase to 137 s-1 hydrolysis of VX.99 Whereas Cherny et al. used 
computationally directed evolution to increase the kcat/Km for OPH against VX from wild type 
OPH 0.94×104 to 499×104 M-1 min-1.50 While promising, these efforts compromise the 
generalizability of OPH reducing the effectiveness for multiple nerve agents. Here, we 
hypothesize that stabilization of the active site increases the probability of the transition state 
formation upon ligand binding. To test our hypothesis, we redesign the protein with a focus on 
interior but not active site residues with potential allosteric interactions that enhance general 
enzymatic activity as assayed by paraoxon and omethoate. We show a rise in the hydrolysis rates 
of OPH with both single and multiple mutations. Since our approach is independent of the OPH 
active site, the combination of our mutations and those from other approaches are potentially 
additive.  
Our design method relies on cycles of computational stability prediction of the enzyme in 
the active state combined with experimental validation. At the conclusion of each iteration we 
apply computational analysis through equilibrium discrete molecular dynamics (DMD), and 
replica exchange DMD to gain additional insight into the effect of each mutation.100–102 When 
applying this method to OPH, we identify five residue positions located between five and ten Å 
from the active site that increase activity against paraoxon by one order of magnitude 
experimentally. The successfully redesigned OPH demonstrates a potential application of this 
computational protocol to enhance native enzymatic activity.  
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Results 
 
Prediction and experimental validation of single mutations.  
 
We hypothesize that stabilizing the protein active site through protein design will 
stabilize functionally relevant states and increase the activity of the protein. Utilizing the known 
crystal structure (PDB ID: 1DPM), we estimate the changes in protein stability by calculating 
ΔΔG, the free energy difference between the folded and unfolded states after mutation, using the 
protein stability prediction algorithm, Eris.103,104 We identify hotspot residues, residues where 
mutation significantly improves the estimated ΔΔG values, for all possible single- or multiple-
mutations away from the active site (Methods and Figure 3.2). 
 
Figure 3.2 Residues selected for mutation consideration. OPH monomer with the bound 
ligand (green), metal coordinated atoms (spheres), active site residues (lines), and the residues 
located between five and ten Ǻ beyond zinc ions considered by the protein stability scan 
(highlighted in magenta). 
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 The results from scanning OPH for single-mutation indicated five mutations that 
significantly (Z-score < -1.5) increase stability: T54M, D105T, T199I, C227M, and G251L with 
ΔΔG scores of -5.0, -6.7, -8.1, -3.8, and -6.7 kcal/mol respectively (Table 3.1). Examination of 
the wild type crystal structure reveals that these residues are either near an internal void formed 
by residues T54, T199, C227 and G251, or corresponding to a buried charge, D105 (Figure 3.3a-
b). The stabilization effect is either due to increases of the side chain volume to fill the cavity or 
to reduce the desolvation penalty of buried charges. 
 
 
Figure 3.3 Identified mutation positions. A) Hotspot results of residue positions G251, C227, 
T199, and T54 (magenta) surrounding an internal void shown in mesh surface. B) Residue 
position D105 (magenta) showing a buried polar amino acid. All structure figures created using 
Pymol.105 
  
4
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Table 3.1 Predicted stability scores and experimental data. The predicted stability scores are a result of our scan of potential 
mutations using Eris for single, double, and triple mutations with associated Z-score. Also shown is the experimental data obtained for 
each mutation combination for paraoxon and omethoate. 
Mutation 
Predicted Stability   Paraoxon   Omethoate 
ΔΔG 
(kcal/mol) Z-score   kcat (s
-1) Km (mM) kcat/Km (s-1 M-1)   kcat (s-1) Km (mM) 
kcat/Km  
(s-1 M-1) 
OPH - -  907±18 0.898±0.059 (101±6.9)×10
4  (75.8±4.4)×10
-4 0.838±0.272 9.04±3.0 
T54M -5 -2  1240±37 0.378±0.053 (32.9±4.7)×10
5  (37.3±2.6)×10
-4 0.208±0.154 18.0±13 
D105T -6.7 -2.7  - - -  - - - 
T199I -8.1 -3.3  950±20 0.340±0.035 (27.9±2.9)×10
5  (53.7±7.1)×10
-4 1.21±0.55 4.43±2.1 
C227M -3.8 -1.5  35.1±1.4 0.133±0.037 (26.3±7.5)×10
4  (173±8.8)×10
-4 0.485±0.172 35.6±13 
G251L -6.7 -2.7  - - -  - - - 
T199I/T54I -12.5 -2.57  1260±150 0.703±0.31 (17.9±8.2)×10
5  (46.6±10.6)×10
-4 3.41±2.1 1.37±0.89 
C227M/T199I -10.312 -2.05  112±1.6 0.158±0.015 (70.7±7.0)×10
4  (125±19)×10
-4 2.86±1.4 4.39±2.2 
C227M/T54I -6.06 -2.4  193±8.3 0.139±0.043 (13.9±4.3)×10
5  (2510±340)×10
-4 17.4±3.6 14.5±3.6 
C227M/T199I/T54I -14.85 -3  553±12 0.130±0.020 (42.5±6.7)×10
5  (4390±590)×10
-4 5.04±1.6 87.1±31 
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To assess the utility and accuracy of our computational methods we verify our 
predictions experimentally. Wild type and mutant OPH are expressed in traditional E. coli. The 
activity of OPH and mutants are measured and compared using paraoxon, a G-agent analog and 
omethoate, a V-agent analog. The activity of purified wild type OPH for paraoxon is kcat of 907 
s-1.  The OPH mutations T199I, C227M, and T54M each displays measurable catalytic kinetics 
against paraoxon with kcat values of 950 s-1, 35.1 s-1, 1240 s-1, respectively (Table 3.1). Mutants 
G251L and D105T have no apparent activity. The relationship between the OPH mutants and 
wild type shows modulated activity with mutants T199I and T54M improve activity over wild 
type by 5% for T199I and 37% for T54M. 
When we test wild type OPH and mutants against omethoate, a V-agent analog, we find 
that the mutants T54M (kcat = 37.3×10-4 s-1) and T199I (kcat = 53.7×10-4 s-1), perform in the 
same order of magnitude as wild type OPH (kcat = 75.8×10-4 s-1). Yet the mutant C227M 
increases the activity by one order of magnitude to a kcat of 173×10-4 s-1, suggesting that each of 
the mutations, though located outside of the active site, affect the specificity of OPH for the 
different classes of agents as supported by the observations that T199I improves paraoxon 
activity, yet only C227M improves omethoate activity. 
 
Prediction of double and triple mutations with experimental validations.  
 
With the experimentally verified three hotspot residues, T54, T199 and C227, we extend 
our ΔΔG calculation for all possible double and triple mutations. Based on Eris calculations, we 
identify the following stabilizing double-mutants: T54I/T199I, T54I/C227M, and T199I/C227M; 
and triple-mutant: T54I/T199I/C227M (Table 3.1). We note that the stabilizing double- and 
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triple-mutations are not a simple combination of the stabilizing single-mutations, which is due to 
the coupling of these residues. For example, T54I was not as stabilizing as T54M in single 
mutation but becomes more stabilizing when combined with other mutations. The mutation 
combinations with the largest favorable change in calculated stability include those with T199I. 
For example, T199I alone has a predicted ΔΔG of -8.1 kcal/mol, but when combined with 
C227M the predicted score improved to -10.3 kcal/mol. Additionally, when T199I is combined 
with T54I the improved stability increased to a total predicted score for the double mutation 
T54I/T199I of -12.5 kcal/mol (Table 3.1). 
 
 
Figure 3.4 Illustrative example of kinetic data. We show an example of a standard Michaelis-
Menton kinetic plot of the activity of the double mutation T199I/T54I performed at room 
temperature. 
 
We also test these double and triple mutations experimentally and find that only the 
double mutant T199I/T54I increases paraoxon activity over wild type OPH (Table 3.1, Figure 
3.4). When we test against omethoate we find that mutations containing C227M, specifically 
C227M/T199I (kcat = 125×10-4 s-1), C227M/T54I (kcat = 2510×10-4 s-1), and C227M/T199I/T54I 
(kcat = 4390×10-4 s-1) increase the activity up to two orders of magnitude above the wild type kcat 
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of 75.8×10-4 s-1 (Table 3.1). It is interesting to note that against paraoxon the mutations with 
T199I increase activity, whereas against omethoate the mutations with C227M improve activity. 
This finding suggests that allosteric modulation potentially acts to modify the specificity of the 
active site. 
 
Computational analysis of thermostability and conformational dynamics.  
 
Having completed the first few cycles of computational design and experimental 
verification. We seek to gain insight into the effects of mutations, specifically to identify any 
mechanisms that may explain the differing specificity upon allosteric mutation. Usually, a 
mutation that affects the stability of the entire protein is manifested by the change in the melting 
temperature, Tm. Additionally, the proposed mutations would impact the active site through 
allosteric coupling.88,106,107 Hence, we computationally investigate our predicted and 
experimentally validated single, double and triple OPH mutations for both thermal stability and 
altered active site dynamics. Our first computational analysis examined the effect of OPH 
mutations on protein stability using replica exchange DMD combined with the weighted 
histogram analysis method to calculate the specific heat (Cv).100,101 The computed Cv plot allows 
us to extrapolate an estimated Tm by identifying the temperature at which the specific heat 
reaches its maximum value. An increase in Tm indicates an increase in thermal stability. Single 
mutations T199I, C227M, and T54M have a similar Tm, varying from wild type OPH by ± 5 K 
(Figure 3.5 and Appendix Figure A.1).  
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Figure 3.5 Melting temperature calculated from computational simulations. We show a 
comparison of the best single mutation, T199I (red), double mutation, T54I/T199I (blue), and 
triple mutation, T54I/T199I/C227M (green), with wild type OPH (black), specifically, the 
reaction coordinate obtained from replica exchange DMD processed by WHAM. 
 
In addition, though G251L has a similar Tm, it, like D105T, disrupts the major transition 
peak creating multiple states that are non-functioning (Appendix Figure A.1). The double 
mutants are slightly destabilizing with a ΔTm ranging from -5.03 to -10.06 K. Triple mutant 
T54I/T199I/C227M is destabilizing with the Tm of 329.4 K as compared to wild type OPH of 
334.4 K (Table 3.2 and Appendix Figure A.1). Through comparing OPH mutants to wild type 
OPH we establish that the predicted mutations have no significant impact on calculated thermal 
stability, with only slight variations in Tm, suggesting that no mutation with activity detrimentally 
destabilizes the protein on a global scale.  
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Table 3.2 Specific heat calculations. Calculated specific heat (CV) and melting temperature 
(TM) for each mutation combination using replica exchange DMD and weighted histogram 
analysis. 
Mutation TM (K) ΔTM (K) CV (kcal /mol*K) 
WT 334.4 - 18.24 
C227M 331.9 -2.50 15.12 
T54M 335.6 1.25 14.08 
T199I 334.4 0.00 14.26 
C227M/T54I 328.1 -6.25 16.18 
C227M/T199I 320.6 -13.75 13.89 
T199I/T54I 326.9 -7.50 15.59 
C227M/T199I/T54I 329.4 -5.00 16.67 
    
 
Without significant changes in stability, we examine the conformational dynamics of 
wild type OPH and mutants to understand the affect on the active site. We perform ten 
independent DMD simulations with randomized initial velocities for each mutant at a 
temperature of ~311 K. This temperature was chosen as it is ~10 K lower than the Tm of the least 
stabilized mutation, T199I/C227M. We perform these simulations to identify changes in residue 
fluctuations between wild type and mutant OPH by calculating the RMSF for each of the 10 
trajectories and averaging them (Figure 3.6). Our analysis reveals four segments — residues 80-
90, 207-224, 261-276, and 311-323 — that represents a significant (p-value < 0.05) change in 
RMSF (Table 3.3). 
Comparing the behavior of these segments across the OPH mutations, the second 
segment is significantly (p-values < 0.01) rigidified by all mutations with ∆RMSF ranging from -
2.93 Å for mutation T54I/T199I to -6.27 Å for mutation C227M.  
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Figure 3.6 Fluctuation analysis of computational simulations. We show the root mean square 
fluctuation per residue over 1,000,000 time steps of equilibrium DMD simulations. Each 
mutation is an average of ten equilibrium DMD runs with a setting of 0.62 reduced temperature 
units. We use a tube representation of protein structures, where the backbone trace radii are 
rescaled according to fluctuations and colored from stable (blue) to highly varying (red), to 
illustrate changes in fluctuations upon mutations. Highlighted segments represent those 
differences that have somewhat significant to significant values (p-value < 0.05 and < 0.01 
respectively). Corresponding segments and fluctuations are mapped to the crystal structure (PDB 
ID 1DPM). The asterisk on segment 2 indicates a highly significant change across all mutation 
combinations. 
 
Table 3.3 Analysis results of computational simulations. Allosteric mutations change 
dynamics of four segments coupled to the active site. We show the change in fluctuation distance 
(ΔRMSF) as measured in Å with calculated p-values for each segment per mutation 
combination. The values we use in these calculations are obtained from an average of ten 
equilibrium DMD simulations per mutation. All values listed are at least somewhat significant 
(p-value < 0.05). Values highlighted are significant with a p-value < 0.01. 
 Mutation 
Segment 1 Segment 2 Segment 3 Segment 4 
∆RMSF (p-value) ∆RMSF (p-value) ∆RMSF (p-value) ∆RMSF (p-value) 
C227M - -6.27 Å (5.66×10-5) 2.55 Å (2.70×10-2) 1.75 Å (4.30×10-3) 
T54M -2.70 Å (1.55×10-2) -6.20 Å (2.35×10-5) - 2.85 Å (9.85×10-4) 
T199I - -4.79 Å (3.79×10-3) 3.56 Å (3.35×10-2) 1.81 Å (5.23×10-3) 
C227M/T54I - -6.19 Å (7.09×10-5) - 1.76 Å (4.72×10-2) 
C227M/T199I - -6.24 Å (2.64×10-6) 2.01 Å (3.90×10-2) 1.53 Å (7.65×10-3) 
T199I/T54I 2.58 Å (1.01×10-2) -2.93 Å (2.57×10-4) - 1.63 Å (9.15×10-3) 
C227M/T199I/T54I 2.47 Å (1.11×10-2) -5.54 Å (2.27×10-4) 2.84 Å (2.22×10-2) 2.25 Å (1.59×10-2) 
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Whereas in the first segment the majority of mutations result in increased flexibility compared to 
the wild type; such as T54M/C227M (+2.00 Å), T54I/T199I (+2.58 Å), and T54I/T199I/C227M 
(+2.47 Å) (Table 3.3). The one exception is T54M, which significantly rigidified the first 
segment, ∆RMSF = -2.70 Å. Note that single mutant T54M has an increased kcat for paraoxon 
activity but a reduced kcat against omethoate as compared to wild type OPH. Both of the 
remaining segments show somewhat increased flexibility from many of the mutations with 
segment three having a ∆RMSF range from 2.01 Å (T199I/C227M) to 3.56 Å (T199I) and 
segment four ranging from 1.53 Å (T199I/C227M) to 2.85 Å (T54M). Figure 3.6 shows the 
average RMSF of wild type OPH with the best performing single mutant T199I (red), double 
mutant T54I/T199I (blue), and triple mutant T54I/T199I/C227M (green) (Appendix Figure A.2).  
 
Discussion 
 
Organophosphates have presented a significant threat since their induction as weaponized 
nerve agents. The limited effectiveness of current countermeasures has spurred many 
investigative efforts with the majority of studies focusing on redesign of active-site residues of 
known organophosphate hydrolyzing enzymes, such as OPH. To further improve the activity of 
OPH and its variants, we seek an orthogonal approach to enhance general enzymatic activity by 
investigating OPH mutations with an allosteric effect on the active site. For this purpose, we 
create and implement a general workflow with applications to any enzyme or protein utilizing a 
molecular design suite based on the Eris algorithm, for rapid estimation of changes in 
thermodynamic stability upon mutation.103  
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 Using this protein design protocol, we identify five single mutations, T199I, T54M, 
C227M, G251L, and D105T. When we express them experimentally, three of the mutations, 
T199I, T54M, and C227M show measurable kinetic rates. By examining them computationally 
by replica exchange DMD100, we find the derived specific heat profile of the mutants with no 
activity (G251L and D105T) shows no well-defined folding/unfolding transition peak (Appendix 
Figure A.1).  
 When we examine the affects of the mutations on omethoate activity compared to 
paraoxon activity, we observe that the mutations with T199I provide the most enhancement of 
activity for paraoxon whereas a different mutation, that of C227M, provides the greatest increase 
in omethoate activity. This observation suggests that our allosteric mutations not only affect 
activity levels, but may also impact ligand specificity. Future efforts will concentrate on 
understanding the mechanism by which these mutations affect the ligand specificity. 
The computational investigation revealed that the activity enhancement of the single, 
double, and triple mutations is due to allosteric effect on the active site. Our RMSF analysis of 
both wild type and mutant OPH variants indicated that residue segments 80-90, 207-224, 261-
276, and 311-323 are dynamically coupled to the mutation sites. Correlation with the catalytic 
activities of various mutations suggested that concerted dynamics of a whole protein are 
important for the catalytic function and that rigidification of segment 2 and increased flexibility 
of other segments are related to the enhancement of catalytic activity (Figure 3.6).  
In summary, we have described a generalizable approach to enzyme enhancement that 
focuses on allosteric mutations away from the active site. Such an approach offers an additional 
handle to control protein active cites that are otherwise sensitive to direct modification. The 
central hypothesis is that increasing the stability of the catalytically-active state of an enzyme 
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may increase the population of this state and thus enhance the activity. Experimental 
characterizations combined with additional computational analysis using DMD simulation 
suggests that thermo-stability estimation may further improve the prediction accuracy. Further 
dynamics analysis confirmed the allosteric effect of our proposed mutations and revealed the 
coupled dynamics important for the catalytic activity of OPH. In total, this work adds a new 
dimension to the field of protein design and pushes the boundaries for allosteric engineering 
through our developed tool of protein stability prediction that we use to enhance the catalytic 
activity of organophosphate hydrolase increasing the kcat of wild type OPH by one order of 
magnitude for paraoxon and two orders of magnitude for omethoate.  Since the allosteric 
mutations are away from the catalytic sites, we expect our approach can be combined with other 
active-site-oriented methods to maximally enhance the activity of OPH. 
 
Methods 
 
Protein stability prediction. Using our in-house developed protein stability algorithm, Eris, we 
identify mutations that stabilize OPH. The stability of the protein is quantified by the change in 
free energy (ΔΔG) between the wild type protein and its mutant. Using the high-resolution dimer 
structure of OPH (PDB ID: 1DPM), we exclude the residues that coordinate the zinc and are in 
contact with the substrate. We also exclude the surface residues to reduce possible interruption of 
protein-protein interactions of OPH. The mutated residues included 53-56, 58, 59, 61-67, 72, 73, 
79, 82, 83, 86, 87, 90, 98-105, 107-110, 112, 113, 116, 124-135, 139, 150, 153, 167-172, 175-
181, 183, 184, 198-202, 204-212, 215, 216, 227-235, 239, 240, 243, 250-263, 265-270, 273-278, 
280, 281, 297-300, 304-307, 309-316, 318-329, and 331-332. For each residue, the native amino 
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acid is mutated to the other 19 types. For each sequence (wild type and mutants), we perform 
100 independent Monte-Carlo-based protein side-chain repacking using Dunbrack rotamer 
library108 and all energy calculations utilize the MedusaScore scoring function61. With these 100 
independent Medusa runs, we compute the average stability <ΔG> and its standard deviation 
δ(ΔG). For any given mutation, we obtain the average ΔΔG by subtracting the wild type protein 
stability, <ΔG>mut-<ΔG>wt. The corresponding Z-score is obtained. 
 
  !"#  ∆∆%[&	∆%'(  &	∆%)(] (3.1) 
 
Our scanning study suggests that the majority of the positions do not have strong stabilizing 
mutations and only a few hotspots can be mutated to increase the stability with significant Z-
scores (Z-score < -1.5). 
 
Site-directed mutagenesis. Site-directed mutagenesis is performed using Quikchange II kit from 
Agilent. Primers are designed according to manufacturer’s protocol and purchased from IDT. 50 
µl of PCR reaction containing 5 µl of 10x reaction buffer, 1 µl dNTP mix, and 1.25 µl of each 
forward and reverse primers, 1 µl pfu ultra polymerase, and 10 ng DNA template is used for 
mutagenesis reaction. The PCR cycles are: 95 °C, 2 min, 30 cycles of 95 °C, 1 min, 55 °C, 1 min 
and 72 °C, 1.5 min, followed by 72 °C, 10 min. The resulted PCR products are DpnI digested 
and then transformed into XL1-blue supercompetent cells.  
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Plasmid preparation. Plasmids are prepared using Invitrogen maxiprep kit with sequences 
confirmed by Eurofin operon. Plasmid concentrations are determined using nanodrop and 
adjusted to 1 µg/µl. 
 
E. coli expression and purification. The wild type and mutant plasmids are cloned into our 
expression vector of pET14B and expressed in the E. coli strain BL21 (DE3) pLysS. A poly-His 
tag is added to the mutant T54M located on the C-termini to aid in purification. The cells are 
grown in standard LB and induced by 1 mM Isopropyl β-D-1-thiogalactopyranoside (IPTG) at 
25°C overnight. We resuspend the collected cell pellets in 50 mM tris, 500 mM NaCl at a pH of 
7.4 with 40mM imidazole, 5 mM βME, and 0.1 μM pepstatin. The cells are lysed using 
sonication and then centrifuged at 15,000 g for two hours. The collected supernatant is filtered 
through a 0.22 μm syringe filter and loaded on a 5 mL HisTrap FF column from GE. The 
proteins are eluted by a gradient to 50 mM tris, 150 mM NaCl at a pH of 7.4 with 1 M imidazole. 
We determine protein concentration for E. coli expression system proteins using a nanodrop to 
measure A280/A260. 
 
OPH activity assay. Using a SpectraMax i3 plate reader we perform kinetic assays measuring the 
absorbance of the paraoxon leaving group at 405 nm or the Ellman marker at 412 nm. Various 
levels of paraoxon or omethoate for final concentrations of 0, 0.5, 2, 4, 6, 8, 10, and 12 mM is 
added to a buffer containing 50 mM bis-tris-propane and 75 µM of ZnCl2, pH = 7.4. For 
omethoate 2 µL of the 5 mM Ellman reagent is added. 
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Computational Analysis. All-atom DMD simulations are used to study both thermodynamic 
properties and the conformational dynamics of OPH. Specifically, we perform replica exchange 
DMD simulations with 52 replicas ranging from 0.50 to 0.70 kcal/mol/kB incrementally by 0.004 
kcal/mol/kB. Each simulation is run for 1x106 DMD time steps with a temperature exchange 
every 1,000 DMD time steps. Each DMD time step corresponds to ~50 fs, and the total 
simulation time of each replica is ~50 ns. We then apply the weighted histogram analysis method 
to calculate the specific heat as a function of temperature109, which is further used to determine 
the thermal stability of the mutants with respect to the wild type protein. 
Constant temperature equilibrium simulations of OPH and mutants are performed at 0.62 
kcal/mol/kB; this temperature is well below the folding transition temperature (Figure 3.5 and 
Appendix Figures 1-2). To identify any major motion deviations we compute an average of the 
root mean square fluctuations (RMSF) per residue. We perform ten independent simulations for 
each mutation and wild type protein. From each independent trajectory we consider only the time 
points after the protein reaches equilibrium, ~300,000 time steps. The RMSF per residue is 
calculated using the analysis tool g_rmsf from Gromacs110,111 then averaged to obtain the final 
RMSF for comparisons.  
 
  
  55
 
CHAPTER 4: CONCLUSIONS AND FUTURE DIRECTIONS 
 
 In this work, we have investigated potential solutions to the organophosphate nerve agent 
(OPNA) problem. OPNAs are small molecules with a chiral phosphate that upon exposure, 
quickly inhibit acetylcholinesterase (AChE) preventing signals across the synaptic junctions. The 
usual route of exposure is by inhalation or skin contact. Many of these OPNAs have no scent or 
color, thus making them difficult to detect. This difficulty potentially leads to many unplanned 
exposures of our armed forces, first responders, and civilians during warfare or terrorist attacks. 
An effective method of protection is needed. Though OPNAs have been around for ~70 years 
there has been no significant progress made in protection efforts. There have been successes in 
both detecting the presence of OPNAs via an AChE biosensor and in decontamination by 
organophosphate hydrolase (OPH).73,112–114  
The ultimate goal of this project is a prophylactic protection method via small proteins 
that can sequester OPNAs in a stoichiometric manner (stoichiometric bioscavenger) or hydrolyze 
the OPNAs in a catalytic manner (catalytic bioscavengers). The benefits for such a prophylactic 
measure would be immense. To tackle this problem we chose a two-prong approach, that of 
designing a stoichiometric bioscavenger in concert with a catalytic bioscavenger.  
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Stoichiometric bioscavenger 
 
For the stoichiometric bioscavenger we first identified an alternative to 
butyrylcholinesterase (BChE), the current strongest candidate. The limitations on BChE include 
large molecular weight and mass production issues. The benefits to BChE include the lack of an 
immunological response from injection as BChE is a human plasma derived protein. We 
introduced a computational workflow designed to search a library of known protein structures to 
discover promiscuous activity. Our source library was a subset extracted from the protein 
database (PDB), limited to those proteins below 40 kDa and with monomeric biological 
assembly. This refined structure library was searched to identify proteins capable of covalent 
binding similar to AChE and BChE, specifically those proteins containing residues oriented in a 
proper way to form a catalytic triad. Our search method included a rigid substructure search 
algorithm, Erebus59, in which we extracted the key atoms from the active site of AChE and 
submitted them as the search query. The over 200 results we obtained were visually inspected to 
remove duplicate proteins and ensure surface accessibility of the matched site. The remaining 21 
proteins were excruciatingly examined using molecular docking. Specifically we utilized 
MedusaDock60–62 to simulate the non-covalent interactions between the small molecule VX and 
our candidates. This screen of the 21 candidates led to three candidates chosen for further 
analysis and experimental validation. These candidates are antigen 85-A and phosphoribosyl 
isomerase from Mycobacterium tuberculosis and Smu. 1393c from Streptococcus mutans.  
We validated the interaction potential of each candidate through incubation with a serine 
hydrolase probe, designed to covalently bind and label in the same manner as an OPNA (Figure 
1.2). The only positively labeled candidate was Smu. 1393c indicating a covalent bond 
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formation. To further investigate non-covalent interactions we used the same probe and 
performed a fluorescent polarization experiment to indicate that both antigen 85-A and 
phosphoribosyl isomerase interact with the serine hydrolase probe. We validated the location of 
the predicted covalent interaction of Smu. 1393c by creating a Ser99 to alanine mutation and we 
found the loss of covalent binding confirms the correct prediction of an active site. We 
implemented additional experiments to test the protective potential of Smu. 1393c to protect 
AChE from inhibition by demeton-S-methyl and diisopropylfluorophosphate, V-agent and G-
agent analog respectively. We found that Smu. 1393c helps AChE retain ~75% of it’s original 
activity after exposure to the analogs. Additionally, Smu. 1393c hydrolyzes the V-agent analog 
omethoate and when expressed with zinc hydrolyzes the G-agent analog paraoxon. 
Future investigations will increase our understanding of the mechanism behind Smu. 
1393c hydrolysis of both agent classes. Our ultimate goal is for Smu. 1393c to become a broad-
spectrum bioscavenger therapeutic. To accomplish this goal we must increase the catalytic 
properties for the G-agents and the V-agents. Our best chance will be to engineer two different 
bioscavengers from the same Smu. 1393c platform, one specializing in G-agents, the other in V-
agents. Prior to engineering efforts it is important to obtain a crystal structure co-crystallized 
with zinc and OPNA analogs, both paraoxon and omethoate. Once obtained, this crystal structure 
will become the basis for improved redesign. The process we will utilize is similar to that applied 
to OPH in chapter 3. We will first examine the residues in the active site using Eris103 to estimate 
the ΔΔG, or the stabilization cost of mutating each residue in the active site. One feature of Eris 
that will be useful is the ability to estimate the ΔΔG with a rigid ligand bound. Once we have 
discovered mutations that strengthen the stability of the protein with the rigid ligand bound, we 
will then proceed to simulate the molecular docking potential of this new recombinant, using 
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MedusaDock60,62. If the result of the docking study analysis, similar to what was described in 
chapter 2, is favorable then these candidates will proceed to experimental verification. Based on 
the experimental outcome this process is repeated and guided in an iterative fashion. The end 
result is expected to be either 1) a bioscavenger candidate that can hydrolyze both agents or 2) 
multiple bioscavenger candidates built on the same framework so that when administered in 
concert provide the broadest protection against the most OPNAs as possible.  
 
Catalytic Bioscavenger 
 
Organophosphate hydrolase (OPH) is a known catalytic bioscavenger for various OPNAs 
with applications in decontamination. We examined OPH to see if there are stabilizing mutation 
hotspots occurring outside the active site but close enough to affect the performance and stability 
of the active site. We used our mutation stabilization software, Eris103, to screen each residue 
position that falls between five and ten angstroms from the active site. After scanning this second 
shell set of residues we found five positions with mutations that are potentially stabilizing, 
T54M, D105T, T199I, C227M, and G251L. Four of these residue locations line an internal void 
and the mutations help to fill that void to stabilize the protein and position D105 represents an 
internal polar residue (Figure 3.3). When we examined the effect that each mutation has on OPH 
we find that mutations G251L and D105T do not express or show no activity with computational 
simulations supporting this conclusion by showing that neither G251L nor D105T increase 
calculated stability. Therefore, mutations G251L and D105T were not included when 
considering multiple mutations. The multiple mutation combinations that included T199I have 
activity levels increased for G-agent analog, paraoxon. Whereas when considering the level of 
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activity against omethoate, the V-agent analog, we found that mutations containing C227M show 
a greater increase in activity. This finding interestingly indicates that despite the distance from 
the primary active site, that allosteric mutations not only positively affect activity levels but also 
can assist modulating the specificity of the active site for different OPNAs. Therefore the 
combination of T199I/T54I provides a 40% increase in activity against paraoxon, and mutation 
C227M/T54I provides a 3,300% increase in omethoate activity, and mutation 
C227M/T199I/T54I provides a 5,700% increase also in omethoate activity.  
We have shown that by using purely computational means we have successfully 
increased the activity of OPH for both G- and V-agent analogs, paraoxon and omethoate 
respectively. Because the location of these mutations lie outside the realm of the active site it is 
hoped that they can be successfully combined with active site mutations to increase both 
specificity and activity. To make OPH a therapeutic bioscavenger it will be necessary to engineer 
two specific recombinants, one designed for G-agent protection and another for V-agent 
protection. The process involves first testing our current mutations against live OPNAs. This is 
possible through an established collaboration with Dr. Steve Harvey and Dr. Douglas Cerasoli. 
Once we have OPNA hydrolysis results we will continue designing an improved OPH protein 
through iteration of the procedure outlined in chapter 3. In concert with experimental efforts we 
will seek to simulate changes to the active site by these mutations in an endeavor to understand 
how allosteric mutations affect ligand specificity. We plan on using discrete molecular dynamics 
(DMD) in conjunction with MedusaDock to better understand the change in binding conditions 
upon mutation.  
In the next iteration we will extend the residues considered for mutation from the second 
shell to the third shell. This iterative process, including testing our designs with OPNAs will help 
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us develop the best set of mutations for both agent classes. Once we have exhausted all design 
possibilities in this iterative manner it would be interesting to study the effects of combining our 
mutations with mutations derived from specific active site mutations. Overall, in the process of 
designing OPH we have made progress in understanding the effects of allosteric modulation and 
the direct impacts of allostery on enzyme performance.  
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APPENDIX A: SUPPLEMENTAL MATERIAL FOR CHAPTER 3 
 
 
 
Figure A.1 Specific Heat plots for all mutations. Replica exchange DMD simulations with 
WHAM applied displaying calculated specific heat reaction coordinates for single (A), double 
(B) and triple (C) mutations. 
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Figure A.2 Root Mean Square Fluctuations for all mutations. We show the RMSF observed 
from an average of ten equilibrium DMD runs per mutation at a reduced temperature of 0.62. 
Panel A) single mutations, B) double mutations and C) triple mutations. 
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